IRRAS announced that it received regulatory clearance from the United States Food, Drug, and Administration (FDA) to active all of the functionality on the next generation control unit for its product, IRRAflow, the and only active fluid exchange system. Earlier this year, IRRAS introduced this next-generation IRRAflow system, which included embedded interactive tutorials, intuitive software with upgraded graphics, refined treatment workflow, and a new drainage collection design, to its customers in the US. This most recent FDA 510(k) clearance extends the system's previous FDA clearances and permits the activation of software functionality that connects to the patient's bedside monitor and openly transmits treatment information to the central nursing station.

The IRRAflow system advances treatment options for patients suffering from intracranial bleeding as the first irrigating drainage system that enables active fluid exchange. IRRAflow combines automated irrigation, controlled drainage, and continuous monitoring of the patient's intracranial pressure (ICP) into one intelligent system. Its unique mechanism of action uses recurring irrigation to prevent solid particles from blocking the drainage holes on the catheter tip and to also dilute collected toxic material, making it easier to remove.